A detailed history of Ronald Blue Trust, Inc. transactions in Tg Therapeutics, Inc. stock. As of the latest transaction made, Ronald Blue Trust, Inc. holds 1,516 shares of TGTX stock, worth $46,768. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,516
Previous 667 127.29%
Holding current value
$46,768
Previous $11,000 218.18%
% of portfolio
0.0%
Previous 0.0%

Shares

6 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 17, 2024

BUY
$17.21 - $25.28 $14,611 - $21,462
849 Added 127.29%
1,516 $35,000
Q2 2024

Jul 18, 2024

BUY
$13.32 - $19.19 $8,884 - $12,799
667 New
667 $11,000
Q2 2023

Jul 14, 2023

SELL
$15.48 - $35.0 $433 - $980
-28 Reduced 45.9%
33 $0
Q1 2023

Apr 17, 2023

SELL
$10.23 - $19.34 $358 - $676
-35 Reduced 36.46%
61 $0
Q4 2022

Jan 17, 2023

SELL
$5.01 - $11.83 $60 - $141
-12 Reduced 11.11%
96 $1,000
Q3 2022

Oct 21, 2022

BUY
$4.57 - $8.4 $493 - $907
108 New
108 $0

Others Institutions Holding TGTX

About TG THERAPEUTICS, INC.


  • Ticker TGTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 145,274,000
  • Market Cap $4.48B
  • Description
  • TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its therapeutic product candidates include Ublituximab, an investigational glycoengineered monoclonal antibody for the treatment of B-cell non-hod...
More about TGTX
Track This Portfolio

Track Ronald Blue Trust, Inc. Portfolio

Follow Ronald Blue Trust, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ronald Blue Trust, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ronald Blue Trust, Inc. with notifications on news.